A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
NRG HN010
Description
This research study is for patients with salivary gland cancer (SGC) that has the protein HER2 at high levels (HER2-positive) or low levels (HER2-low), and has come back, spread outside of your salivary gland, or cannot be removed by surgery.
If the patient has HER2-positive SGC, they will either get: Docetaxel and trastuzumab for 18 weeks or Ado-trastuzumab emtansine (T-DM1).
If the patient has HER2-low SGC, they will get: DS-8201a (trastuzumab deruxtecan).
Protocol#: NRG-HN010
Study Information
Age Group: Adults
Participating Sites: Sanford Bemidji Region; Sanford Bismarck Region; Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: II
Participating Sites: Sanford Bemidji Region; Sanford Bismarck Region; Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: II
Principal Investigator(s)
Daniel Almquist
, MD
Department
Management Group:
Head & Neck - Oncology; NCORP
NCT:
NCT05408845
Contact Us
For more information on clinical trials at Sanford Health, call one of our regional clinical research offices:
Sanford Bemidji Region: (218) 333-4869
Sanford Bismarck Region: (701) 323-5760
Sanford Fargo Region: (701) 234-2383
Sanford Sioux Falls Region: (605) 328-1368